On Monday, brokerage firm B&K Securities had initiated coverage on Laurus Labs with a “buy” rating and a price target of ₹1,030. The firm said that Laurus Labs is entering a strong growth cycle led by its high-margin CDMO business, which has gradually emerged as the company’s key earnings driver.
